S100A8 / S100A9 (Calprotectin)

Calprotectin is the obligate Ca²⁺-sensing heterocomplex of S100A8 (MRP8/calgranulin A) and S100A9 (MRP14/calgranulin B), two small EF-hand S100-family proteins that are co-expressed and functionally interdependent. It is the dominant cytosolic protein of neutrophils and monocytes (~40–60% of total soluble protein in neutrophils), secreted as a damage-associated molecular pattern (DAMP/alarmin) upon cellular activation, stress, or death. It drives chronic-inflammation via TLR4 and RAGE → NF-κB signalling, and exerts antimicrobial activity through Zn²⁺/Mn²⁺ sequestration (“nutritional immunity”). In aging biology, S100A8 and S100A9 are established components of the SASP, co-upregulated markers of the universal mammalian mortality transcriptomic signature, and mechanistically positioned at the intersection of inflammaging and immune-cell dysfunction.

Identity

Subunit	Common name(s)	UniProt	NCBI Gene	HGNC	Length	MW
S100A8	MRP8, calgranulin A, CP-10, L1Ag (light)	P05109	6279	10498	93 aa	~10.8 kDa
S100A9	MRP14, calgranulin B, BEE22, P14	P06702	6280	10499	114 aa	~13.1 kDa

Ensembl: S100A8 = ENSG00000143546; S100A9 = ENSG00000163220. Both genes are located on human chromosome 1q21.3 in the S100 gene cluster.

Mouse orthologs: S100a8 (MRP8) and S100a9 (MRP14) — one-to-one orthologs; sequence highly conserved.

GenAge: No entry for either subunit in GenAge-human as of the last check. needs-canonical-id (GenAge lookup to confirm; aging relevance established via Tyshkovskiy 2026 transcriptomic signatures rather than GenAge curation).

Complex-page note: This page covers the obligate S100A8/S100A9 heterodimer (calprotectin) as the primary functional unit. Both subunits are expressed together in myeloid cells; S100A9 monomers and homodimers (S100A9/S100A9) exist but with lower affinity for TLR4/RAGE and reduced antimicrobial potency. S100A8 is functionally unstable as an isolated monomer at physiological conditions and requires S100A9 for stability and secretion.

Complex architecture

The S100A8/S100A9 heterodimer assembles with two EF-hand Ca²⁺-binding motifs per subunit (one canonical, one pseudo). Dimerization is Ca²⁺-regulated: Ca²⁺ binding drives a conformational change that exposes a hydrophobic surface on each subunit and stabilizes heterodimer assembly. At elevated Ca²⁺ concentrations (as occur in extracellular milieu or at sites of tissue damage), two heterodimers further assemble into a heterotetrameric (A8)₂(A9)₂ complex — this is the dominant extracellular form and the stoichiometry most associated with DAMP activity and antimicrobial potency.

The S100A9 C-terminal extension (residues ~100–114, absent in S100A8) is required for high-affinity Zn²⁺ chelation via a histidine-rich site bridging both subunits at the dimer interface ¹. Mn²⁺ sequestration uses a separate, transition-metal site in the S100A8/A9 heterotetramer ².

Mechanism of action

1. DAMP / alarmin signalling via TLR4 and RAGE

Released calprotectin (extracellular S100A8/A9) activates pattern-recognition receptors:

TLR4/MD-2 complex — calprotectin acts as a TLR4 ligand (comparable to LPS in terms of downstream pathway, though via a distinct binding mode), activating MyD88 → IRAK4 → TRAF6 → IKK → NF-κB and TRIF → IRF3 → type-I IFN arms ³. In microglia, both ERK and JNK MAP-kinase cascades are co-activated, promoting TNF-α and IL-6 production.
RAGE (AGER) — calprotectin binds RAGE, engaging a positive-feedback loop in which NF-κB-induced RAGE upregulation amplifies the signal ⁴. This feed-forward mechanism is thought to sustain the chronic low-grade inflammation characteristic of aging tissues.

The net inflammatory output: IL-6, IL-1β, TNF-α, IL-8/CXCL8, reactive oxygen species. needs-replication — most mechanistic data derive from cell-culture or murine models; direct TLR4-binding affinity and signalling kinetics in aged human primary cells are not well-characterized.

2. Antimicrobial activity — nutritional immunity

Calprotectin sequesters divalent metals essential for bacterial growth:

Mn²⁺ — sequestered via a His₆ coordination site (His17, His27 of S100A8 + His91, His95, His103, His105 of S100A9) formed across the heterodimer interface; growth inhibition was demonstrated for multiple bacterial pathogens including S. aureus, S. epidermidis, E. faecalis, P. aeruginosa, A. baumannii, S. flexneri, and E. coli ².
Zn²⁺ — sequestered via a separate site involving the S100A9 C-terminal tail; Zn²⁺ chelation is pH-dependent (highest affinity at neutral pH) and distinct from Mn²⁺ binding ¹.

Antimicrobial potency requires the heterotetrameric form and both metal-binding sites. This function is a key mechanism by which neutrophil extracellular traps (NETs) inhibit pathogen growth, and is distinct from the alarmin/DAMP signalling function.

3. Intracellular roles

Inside myeloid cells, S100A8/A9 participates in:

Cytoskeletal regulation — associates with tubulin and actin networks; contributes to neutrophil shape changes and migration
NADPH oxidase assembly — interacts with NCF2 (p67-phox), RAC1/2, CYBA (p22-phox), CYBB (gp91-phox); proposed role in regulating the oxidative burst
Arachidonic acid transport — S100A8 has arachidonic acid-binding capacity; may shuttle substrate to prostaglandin-synthesis enzymes

These intracellular roles are secondary to the extracellular DAMP function for aging relevance; included for completeness. unsourced — NADPH oxidase interaction claims are from training knowledge and have not been verified on this page against primary sources.

Role in aging

S100A8/A9 as SASP components

Both subunits are expressed in senescent cells and secreted as part of the senescence-associated secretory phenotype (SASP) ⁵. In a three-arm pharmaco-clinical study (ex vivo + 44-woman clinical efficacy trial + 30-woman genomic biopsy cohort), topical application of a niacinamide + hyaluronic acid formula for two months produced significant downregulation of S100A8 and S100A9 at the mRNA level in skin biopsies — both appearing among 24 SASP/aging-related genes significantly reduced (p<0.05, fold-change >1.5 in the 30-woman genomic arm) — correlating with clinical improvement across wrinkle, fine-line, luminosity, smoothness, and plumpness endpoints in the 44-woman arm ⁵. needs-replication — single study; skin-only tissue context. needs-human-replication — the mechanistic role of S100A8/A9 in SASP from non-skin senescent cell types in vivo remains to be established.

Dimension	Status	Notes
Pathway conserved in humans?	yes	TLR4/RAGE signalling is conserved; S100A8/9 genes present in all vertebrates examined
Phenotype conserved in humans?	yes	Calprotectin elevation in frailty, IBD, RA, COVID-19 severity all documented in humans
Replicated in humans?	partial	Biomarker associations strong; SASP causal role in human aging tissue not yet intervention-confirmed

Universal mortality transcriptomic signature (Tyshkovskiy 2026)

The Tyshkovskiy et al. 2026 Nature meta-analysis of >11,000 transcriptomes across four mammalian species provides the strongest cross-species evidence for calprotectin as a genuine aging-biology entity ⁶:

S100a8 is a conserved up-regulated mortality-clock contributor. It is named in the UP driver set of the mortality-clock — the group of genes (including Gpnmb, Cdkn1a, Lgals3, Cst7, Eda2r) whose upregulation is most consistently associated with ageing and expected mortality across species ⁶. This places S100A8 in the same tier as p21 and gpnmb as a canonical pro-aging marker.

S100a8/S100a9 track the U-shaped embryonic tAge trajectory. During embryogenesis, both subunits are downregulated to a minimum at approximately embryonic day E10 (“ground zero”) then re-activated as development proceeds — tracing the U-shaped tAge rejuvenation trajectory described in the paper. This pattern is consistent with the information theory of aging concept of an embryonic “reset point” where the damage/inflammation signature reaches its nadir ⁶.

S100a9 is a shared down-regulated target of heterochronic parabiosis and caloric restriction. In the paper’s shared-rejuvenation signature (Fig 6g — the top genes whose downregulation is common to heterochronic parabiosis (old mice, liver) and caloric restriction (liver), the two contexts that correlate at Pearson r≈0.5), S100a9 is named alongside Cdkn1a, Ccl5 and Lgals3 ⁶. For this CR/parabiosis signature the paper names the S100a9 subunit specifically (not S100a8); it is the broader embryonic ground-zero finding (above) where S100a8 and S100a9 are both explicitly named. Together these place calprotectin — via S100a9 across CR/parabiosis/embryogenesis and S100a8 in embryogenesis — at the convergence of the most robust age-reversing contexts studied, consistent with the subunits’ role as SASP/alarmin drivers whose suppression marks transcriptomic rejuvenation.

Scope discipline. Only claims explicitly stated in the verified Tyshkovskiy 2026 study page are asserted above. The paper does not provide gene-level effect-size statistics broken out for S100a8/S100a9 separately in the main text; the claims above reflect the study page’s documented findings. Do not extrapolate to stronger causal claims without further verification.

Inflammaging and frailty biomarker

Elevated serum S100A8/A9 in elderly individuals is associated with frailty and adverse cardiovascular outcomes. A 2022 prospective two-cohort study in Italian older adults (cohort 1: N=35 pre-frail, mean age 75; cohort 2: N=104 frail, mean age 81) showed that elevated circulating S100A8/A9 combined with reduced hematopoietic stem/progenitor cell numbers independently predicted adverse cardiovascular events and all-cause mortality at 1-year follow-up. S100A8/A9 upregulation in HSPCs from bone marrow was >10-fold and from peripheral blood was >200-fold in subjects with greater physical frailty. S100A8/A9 predicted all-cause mortality independently of age and cancer (HR 2.28; 95% CI 1.20–4.31; p=0.012); MACE prediction by S100A8/A9 was borderline after adjustment (unadjusted p=0.043, adjusted p=0.067) ⁷. The dual signal — myeloid over-activation (S100A8/A9 ↑) combined with HSPC depletion — resembles the CHIP/inflammaging profile. needs-replication — two Italian cohorts; independent replication in other populations warranted.

A 2026 review in Ageing Research Reviews (Wang S et al., PMID 41903862) identifies S100A8/A9 as “a central hub in inflammaging” connecting age-associated inflammation across multiple organ systems via the TLR4 axis and proposes that targeting the S100A8/A9–TLR4 pathway may extend healthspans [^wang2026]. no-fulltext-access — DOI 10.1016/j.arr.2026.103108 is confirmed real (PMID 41903862) but the full text is not in the archive (not OA at time of check 2026-05-29); citation relies on PubMed abstract only.

Clinical calprotectin biomarker context

Fecal calprotectin (reflecting intestinal neutrophil burden) is a validated clinical biomarker for IBD activity (sensitivity ~80%, specificity ~90% for distinguishing IBD from IBS in systematic reviews) ⁸. Serum/plasma calprotectin correlates with systemic inflammatory burden across RA, JIA, COVID-19 severity, and sepsis. These clinical validations establish that S100A8/A9 faithfully reports tissue neutrophil/monocyte activation — making elevated serum calprotectin a plausible inflammaging readout in aging cohort studies, though reference ranges in healthy aging populations are not well-standardized. dose-response-unclear

Pathway membership

nf-kb — TLR4/RAGE → NF-κB is the primary downstream effector of extracellular calprotectin
nlrp3-inflammasome — S100A8/A9 have been reported to prime and/or activate the NLRP3 inflammasome; mechanistic details unsourced
jak-stat-pathway — indirect; NF-κB-driven IL-6 secretion feeds forward into JAK-STAT signalling in adjacent cells
cellular-senescence — SASP component; expressed and secreted by senescent cells; connection to p16/p21-arrested cells established in skin context

Key interactors

TLR4 / MD-2 — primary innate-immune receptor for extracellular calprotectin; TLR4/MyD88/NF-κB axis
RAGE (AGER) — second pattern-recognition receptor; drives feed-forward chronic inflammation loop ⁴
S100A8 ↔ S100A9 — obligate heterodimer partners; each requires the other for extracellular stability and full DAMP activity
NCF2 (p67-phox), RAC1/2, CYBA, CYBB — NADPH oxidase components; intracellular interaction (neutrophil oxidative burst)
GAPDH — cytosolic binding; functional significance unclear
TRPM4 — S100A9 interaction; no-mechanism for this interaction
ANXA6 (annexin A6) — S100A9 interaction; role in calprotectin membrane association

Druggability

Open Targets tier 3 (predicted druggable — no aging-validated probe or clinical drug for an aging/inflammaging indication). Several small-molecule approaches are in preclinical development:

Paquinimod (ABR-215757) — a quinoline-3-carboxamide that binds S100A9 and inhibits its interaction with TLR4/RAGE; used in clinical trials for autoimmune disease but not yet for aging ⁹.
Anti-S100A9 antibodies — several in preclinical development for RA and Alzheimer’s disease.
No calprotectin-targeting drug is FDA-approved. The protein surface does not contain a classic small-molecule binding pocket equivalent to a kinase active site; paquinimod’s binding mode is at an allosteric site on S100A9.

needs-canonical-id — Open Targets Platform druggability tier not independently cross-checked via API; tier 3 is a judgment based on preclinical probe (paquinimod) existing without aging-validated clinical use.

Limitations and gaps

#gap/unsourced — intracellular NADPH oxidase assembly role claimed from training knowledge; primary citations not verified on this page.
#gap/no-fulltext-access — Wang 2026 Ageing Research Reviews (PMID 41903862; doi:10.1016/j.arr.2026.103108) is confirmed real but full text unavailable in archive (not OA); cited from abstract only.
#gap/needs-human-replication — SASP role for S100A8/A9 established in skin senescent cells; broader tissue context in human aging requires prospective in-vivo demonstration.
#gap/needs-replication — frailty/cardiovascular outcome association (Bonora 2022) is a single prospective cohort; independent replication warranted.
#gap/dose-response-unclear — age-normative reference ranges for serum/plasma calprotectin in healthy non-diseased older adults are not well-established; clinical cutoffs are disease-context-specific (IBD, RA, sepsis).
#gap/no-mechanism — the molecular mechanism by which S100a9 is specifically suppressed by both heterochronic parabiosis and caloric restriction (from Tyshkovskiy 2026) is unknown.
#gap/needs-canonical-id — GenAge-human entries for S100A8/S100A9 were not found; confirm via direct GenAge lookup.
S100A8 and S100A9 belong to a large S100 family (~25 members in humans); functional cross-talk between family members (S100A6, S100A4, S100A12) in the aging context is incompletely characterized.

Footnotes

doi:10.1002/pro.70294 · n=N/A · in-vitro (biochemical + antimicrobial, recombinant calprotectin + S. aureus) · mechanism · model: C-terminal extension truncation mutants of S100A9; Zn²⁺ chelation requires the S100A9 tail; functions beyond metal sequestration in biomass inhibition ↩ ↩²
doi:10.1073/pnas.1220341110 · n=N/A · in-vitro (biochemical + crystallographic + antimicrobial assay) · mechanism · model: recombinant human calprotectin + S. aureus, S. epidermidis, E. faecalis, P. aeruginosa, A. baumannii, S. flexneri, E. coli; established His₆ Mn²⁺ site (H17, H27 of S100A8; H91, H95, H103, H105 of S100A9) spanning S100A8/A9 interface via crystal structure (PDB 4GGF) + ITC; demonstrated Mn²⁺-sequestration-dependent broad-spectrum antimicrobial activity; 388 citations (archive: confirmed, local PDF available) ↩ ↩²
doi:10.3892/ijmm.2017.2987 · n=N/A · in-vitro (BV-2 murine microglial cells) · mechanism · model: S100A8/A9 stimulation + TLR4/RAGE pathway inhibitors; ERK/JNK/NF-κB activation confirmed; TNF-α/IL-6 production; 190 citations (archive: confirmed, download pending) ↩
doi:10.1084/jem.20070679 · n=N/A · in-vivo (mouse, RAGE-KO) · mechanism · model: RAGE-deficient vs wild-type C57BL/6 in two-stage skin carcinogenesis (DMBA/TPA); S100/RAGE feed-forward loop in chronic inflammation and tumor promotion; 375 citations (archive: confirmed, download pending) ↩ ↩²
doi:10.1038/s41598-024-66624-7 · clinical trial n=44 women (ages 38–55, mean 48) + genomic biopsy cohort n=30 women (ages 35–55) + ex vivo skin explants (3 donors) · in-vivo observational + genomic (NGS-RNAseq) · model: human skin (face + forearm); topical niacinamide+hyaluronic acid formula applied 2 months; S100A8 and S100A9 among 24 SASP/aging genes significantly downregulated (p<0.05, FC>1.5) in biopsy arm; clinical endpoints (wrinkles, fine lines, luminosity, smoothness, plumpness, homogeneity) improved; 15 citations (FWCI 17.8, citation percentile 99th; archive: confirmed, local PDF available) ↩ ↩²
tyshkovskiy-2026-universal-transcriptomic-hallmarks · n=11,165 transcriptomes (3,876 mouse + 663 rat + 2,623 macaque + 4,003 human) · meta-analysis + new in-vivo RNA-seq · model: mouse/rat/macaque/human, >25 tissues; verified wiki page (verified-date: 2026-05-29); S100a8 named in UP mortality-clock driver set; S100a8/S100a9 track embryonic tAge U-curve; S100a9 down-regulated in both parabiosis and CR rejuvenation signatures ↩ ↩² ↩³ ↩⁴
doi:10.1111/acel.13545 · n=35 pre-frail (mean age 75) + n=104 frail (mean age 81) · observational (prospective two-cohort, 1-year follow-up) · model: elderly Italian adults (Northern Italy); frailty-stratified; S100A8/A9 upregulation in HSPCs (>10-fold BM; >200-fold PB in higher-frailty subjects); HR 2.28 (95% CI 1.20–4.31; p=0.012) for all-cause mortality; MACE prediction borderline after adjustment (p=0.067); 8 citations (FWCI 13.5, citation percentile 97th; archive: confirmed green OA, local PDF available) ↩
doi:10.7754/Clin.Lab.2025.250516 · systematic review · model: serum calprotectin across multiple inflammatory diseases (RA, JIA, IBD, COVID-19); clinical specificity and sensitivity summarized; PMID 41543095 ↩
doi:10.3390/biom12040519 · review · model: structural biology of calprotectin receptor interactions; paquinimod binding to S100A9 described; 40 citations (archive: confirmed, download pending) ↩

🧬 Aging Wiki

Explorer

s100a8-s100a9